Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity
Although tirzepatide and semaglutide were shown to reduce weight in randomized clinical trials, data from head-to-head comparisons in populations with overweight or obesity are not yet available.
Rodriguez PJ, Goodwin Cartwright BM, Gratzl S et al. — JAMA internal medicine
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
Oral semaglutide at a dose of 25 mg may provide an alternative treatment option to injectable semaglutide (2.4 mg) and higher-dose oral semaglutide (50 mg) for persons with overweight or obesity.
Wharton S, Lingvay I, Bogdanski P et al. — The New England journal of medicine
Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis
Weight reduction has been shown to alleviate symptoms of osteoarthritis of the knee, including pain. The effect of glucagon-like peptide-1 receptor agonists on outcomes in knee osteoarthritis among persons with obesity has not been well studied.
Bliddal H, Bays H, Czernichow S et al. — The New England journal of medicine
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
In the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in major adverse cardiovascular events in 17,604 adults with preexisting cardiovascular disease, overweight or obesity, without diabetes. Here in this prespecified ana...
Ryan DH, Lingvay I, Deanfield J et al. — Nature medicine
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
The STEP 5 trial assessed the efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg versus placebo (both plus behavioral intervention) for long-term treatment of adults with obesity, or overweight with at least one weight-relat...
Garvey WT, Batterham RL, Bhatta M et al. — Nature medicine
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial
Phase 3 trials have not compared semaglutide and liraglutide, glucagon-like peptide-1 analogues available for weight management.
Rubino DM, Greenway FL, Khalid U et al. — JAMA
Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis
The weight loss benefit of semaglutide in patients with diabetes is well-documented, but its clinical utility in treating obesity among patients without diabetes is less described. We therefore assessed the efficacy and safety of subcutaneous sema...
Tan HC, Dampil OA, Marquez MM — Journal of the ASEAN Federation of Endocrine Societies
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
To explore changes in body weight and cardiometabolic risk factors after treatment withdrawal in the STEP 1 trial extension.
Wilding JPH, Batterham RL, Davies M et al. — Diabetes, obesity & metabolism
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
This trial assessed the efficacy and safety of the GLP-1 analogue once a week subcutaneous semaglutide 2·4 mg versus semaglutide 1·0 mg (the dose approved for diabetes treatment) and placebo for weight management in adults with overweigh...
Davies M, Færch L, Jeppesen OK et al. — Lancet (London, England)
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial
The effect of continuing vs withdrawing treatment with semaglutide, a glucagon-like peptide 1 receptor agonist, on weight loss maintenance in people with overweight or obesity is unknown.
Rubino D, Abrahamsson N, Davies M et al. — JAMA
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial
Weight loss improves cardiometabolic risk factors in people with overweight or obesity. Intensive lifestyle intervention and pharmacotherapy are the most effective noninvasive weight loss approaches.
Wadden TA, Bailey TS, Billings LK et al. — JAMA
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Obesity is a global health challenge with few pharmacologic options. Whether adults with obesity can achieve weight loss with once-weekly semaglutide at a dose of 2.4 mg as an adjunct to lifestyle intervention has not been confirmed.
Wilding JPH, Batterham RL, Calanna S et al. — The New England journal of medicine